Index
RUT
Market Cap
882.58M
Enterprise Value
1.95B
Income
47.91M
Sales
808.21M
Book/sh
9.60
Cash/sh
4.59
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
423
IPO
May 07, 2015
P/E
21.96
Forward P/E
4.01
PEG
-
P/S
1.09
P/B
2.82
P/C
5.91
P/FCF
2.69
EV/EBITDA
4.92
EV/Sales
2.41
Quick Ratio
0.84
Current Ratio
1.03
Debt/Eq
3.90
LT Debt/Eq
3.72
Option/Short
Yes / Yes
EPS (ttm)
1.23
EPS next Y
6.77
EPS next Q
1.86
EPS this Y
0.61%
EPS next Y
-9.38%
EPS next 5Y
-7.75%
EPS past 3/5Y
- 17.92%
Sales past 3/5Y
18.94% 20.28%
EPS Y/Y TTM
34.35%
Sales Y/Y TTM
14.31%
EPS Q/Q
-234.56%
Sales Q/Q
6.32%
Insider Own
2.19%
Insider Trans
-10.24%
Inst Own
122.43%
Inst Trans
5.49%
ROA
2.57%
ROE
17.61%
ROIC
3.25%
Gross Margin
60.02%
Oper. Margin
20.12%
Profit Margin
5.93%
SMA20
-12.54%
SMA50
-19.40%
SMA200
-30.35%
Trades
Shs Outstand
32.50M
Shs Float
31.84M
52W High
50.79 -46.62%
52W Low
25.47 6.44%
Volatility
3.54% 4.67%
ATR (14)
1.57
RSI (14)
32.13
Beta
0.74
Rel Volume
1.36
Avg Volume
519.01K
Volume
704,960
Perf Week
-3.97%
Perf Month
-23.83%
Perf Quarter
-21.24%
Perf Half Y
-39.76%
Perf YTD
-41.45%
Perf Year
-31.40%
Perf 3Y
12.86%
Perf 5Y
34.41%
Perf 10Y
140.34%
Prev Close
27.54
Price
27.11
Change %
-1.56%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-09-25 Initiated Barclays
Overweight
$58
Jan-10-25 Upgrade Needham
Hold → Buy
$46
Jul-30-24 Upgrade H.C. Wainwright
Neutral → Buy
$47
Jun-07-24 Upgrade Jefferies
Hold → Buy
$41 → $44
May-10-24 Downgrade Piper Sandler
Overweight → Neutral
$39
May-10-24 Downgrade Needham
Buy → Hold
Jan-04-24 Downgrade Jefferies
Buy → Hold
$30 → $37
Aug-25-23 Reiterated Needham
Buy
$35 → $36
May-02-23 Resumed Jefferies
Buy
$30
Aug-08-22 Downgrade H.C. Wainwright
Buy → Neutral
Feb-15-22 Upgrade Cantor Fitzgerald
Neutral → Overweight
$18 → $26
Aug-06-21 Downgrade Cantor Fitzgerald
Overweight → Neutral
Jan-11-21 Reiterated H.C. Wainwright
Buy
$29 → $33
Jul-14-20 Initiated BWS Financial
Sell
$8
May-27-20 Initiated Guggenheim
Neutral
Feb-19-20 Resumed Jefferies
Buy
$43
Oct-30-19 Reiterated Needham
Buy
$33 → $25
May-03-19 Resumed H.C. Wainwright
Buy
$23
Apr-12-19 Resumed Janney
Buy
$29
Mar-20-19 Initiated SunTrust
Hold
$22
Show Previous Ratings
Aug-13-26 07:30AM
Aug-06-26 11:27PM
03:03PM
07:57AM
07:30AM
08:00AM
Loading…
Jul-23-26 08:00AM
Jul-20-26 08:00AM
Jun-05-26 08:00AM
May-27-26 08:00AM
May-12-26 07:31AM
May-07-26 04:52PM
07:54AM
07:30AM
Apr-23-26 08:00AM
Apr-08-26 08:00AM
08:00AM
Loading…
Mar-19-26 08:00AM
Mar-10-26 09:04AM
Mar-05-26 08:00AM
Mar-03-26 08:00AM
Mar-02-26 08:00AM
Feb-27-26 03:20PM
Feb-26-26 04:32PM
04:13PM
12:30PM
12:15PM
09:16AM
07:53AM
(Associated Press Finance)
07:36AM
07:30AM
Feb-24-26 10:07PM
10:00AM
Loading…
10:00AM
Feb-23-26 08:00AM
Feb-19-26 10:00AM
09:53AM
08:15AM
Feb-18-26 04:07AM
Feb-12-26 08:00AM
Jan-15-26 08:00AM
Jan-12-26 09:40AM
Jan-08-26 08:00AM
Jan-05-26 09:54AM
Jan-02-26 11:22AM
Dec-31-25 01:04PM
11:24AM
Dec-30-25 08:00AM
Dec-28-25 11:01PM
Dec-26-25 01:42PM
Dec-22-25 09:40AM
09:40AM
Dec-18-25 11:35PM
05:12AM
Dec-14-25 10:31PM
Dec-11-25 11:34PM
12:51PM
Dec-04-25 09:40AM
09:40AM
09:15AM
Dec-03-25 03:45PM
Nov-21-25 08:04AM
Nov-19-25 08:23AM
04:00AM
Nov-18-25 09:40AM
09:40AM
Nov-13-25 12:36AM
Nov-12-25 08:00AM
Nov-07-25 09:50AM
Nov-06-25 03:25PM
02:09PM
09:30AM
08:50AM
08:09AM
07:47AM
(Associated Press Finance)
07:30AM
Nov-04-25 10:22PM
Oct-31-25 11:18AM
Oct-30-25 10:00AM
Oct-29-25 08:00AM
Oct-23-25 08:00AM
12:02AM
Oct-22-25 08:00AM
Oct-13-25 08:00AM
Oct-08-25 11:25AM
Oct-06-25 09:51AM
Sep-25-25 07:19PM
12:00PM
Sep-24-25 11:31PM
Sep-23-25 09:40AM
09:40AM
Sep-02-25 04:07AM
Aug-29-25 05:07AM
Aug-28-25 08:00AM
Aug-25-25 08:00AM
Aug-14-25 01:34AM
Aug-12-25 03:25AM
Aug-11-25 09:33AM
Aug-07-25 02:53PM
09:30AM
08:50AM
07:49AM
(Associated Press Finance)
07:30AM
Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
CEO Mr. Vikram Karnani
Executive VP & CFO Ms. Colleen Tupper
Executive VP Mr. David Dieter
M.D. Dr. Thomas B. Smith FAAFP
Head of Investor Relations Mr. Ian Karp M.B.A.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fallon John A. Former Director Jul 17 '26 Proposed Sale 35.73 13,920 497,429 Jul 17 12:08 PM Fallon John A. Former Director Jul 15 '26 Proposed Sale 36.32 8,095 294,010 Jul 15 04:07 PM SANTINI GINO Director Jun 08 '26 Option Exercise 16.49 8,700 143,463 112,483 Jun 10 04:10 PM Freund John Gordon Director May 18 '26 Sale 34.05 20 681 83,952 May 20 04:05 PM Freund John Gordon Director May 15 '26 Option Exercise 16.49 8,700 143,463 88,099 May 18 04:15 PM Freund John Gordon Director May 15 '26 Sale 34.54 4,127 142,547 83,972 May 18 04:15 PM Freund John Gordon Director May 18 '26 Proposed Sale 34.05 30 1,022 May 18 04:07 PM Lurker Nancy Director May 13 '26 Sale 35.97 4,500 161,861 18,017 May 15 04:05 PM Freund John Gordon Director May 15 '26 Proposed Sale 34.54 4,127 142,547 May 15 10:51 AM BOHLIN GAREN G Director May 11 '26 Option Exercise 16.49 8,700 143,463 70,959 May 13 04:05 PM BOHLIN GAREN G Director May 11 '26 Sale 37.18 8,700 323,491 62,259 May 13 04:05 PM Lurker Nancy Director May 13 '26 Proposed Sale 35.97 4,500 161,861 May 13 12:09 PM BOHLIN GAREN G Director May 11 '26 Proposed Sale 37.18 8,700 323,491 May 11 11:38 AM Dieter David EVP & General Counsel Mar 18 '26 Sale 34.92 13,976 488,099 77,071 Mar 20 05:14 PM Dieter David Officer Mar 18 '26 Proposed Sale 34.92 13,976 488,099 Mar 18 04:10 PM Dieter David Officer Mar 09 '26 Proposed Sale 36.65 6,224 228,110 Mar 09 10:39 AM Dreyer Scott EVP & Chief Commercial Officer Mar 03 '26 Sale 40.41 49,976 2,019,437 71,770 Mar 05 04:29 PM Dreyer Scott Officer Mar 03 '26 Proposed Sale 40.41 49,976 2,019,439 Mar 03 04:10 PM RITA BALICE-GORDON DIRECTOR Dec 05 '25 Proposed Sale 47.03 3,650 171,673 Dec 17 04:01 PM Dreyer Scott EVP & Chief Commercial Officer Dec 08 '25 Option Exercise 15.90 17,600 279,840 121,213 Dec 10 04:32 PM Dreyer Scott EVP & Chief Commercial Officer Dec 08 '25 Sale 48.17 17,600 847,855 103,613 Dec 10 04:32 PM Balice-Gordon Rita J. Director Dec 05 '25 Sale 47.03 3,650 171,673 52,629 Dec 09 04:22 PM Dreyer Scott Officer Dec 08 '25 Proposed Sale 48.17 17,600 847,855 Dec 08 04:11 PM Fallon John A. Director Nov 12 '25 Option Exercise 12.41 34,853 432,578 99,487 Nov 14 04:10 PM Fallon John A. Director Nov 12 '25 Sale 47.21 34,853 1,645,536 64,634 Nov 14 04:10 PM Fallon John A. Director Nov 12 '25 Proposed Sale 47.21 34,853 1,645,536 Nov 12 04:29 PM Tupper Colleen EVP & Chief Financial Officer Nov 06 '25 Sale 40.53 30,000 1,215,753 126,667 Nov 07 04:23 PM Tupper Colleen Officer Nov 06 '25 Proposed Sale 40.53 30,000 1,215,754 Nov 06 04:11 PM Smith Thomas B EVP and Chief Medical Officer Aug 29 '25 Sale 38.42 17,478 671,576 70,264 Sep 03 04:56 PM Smith Thomas B Officer Aug 29 '25 Proposed Sale 38.42 17,478 671,576 Aug 29 02:12 PM
C